Current status of immunological approaches for the treatment of prostate cancer.

ABSTRACT:

Purpose of review

The recent Food and Drug Administration approval of sipuleucel-T for metastatic castration-resistant prostate cancer and of the anticytotoxic T-lymphocyte antigen 4 antibody (Ipilimumab) for metastatic melanoma has led to a renewed interest in immunotherapy for prostate and other cancers. Ipilimumab has entered phase III testing for prostate cancer, as has a viral-based anti-prostate-specific antigen vaccine (ProstVac-VF). Complementing these phase III studies are a number of innovative phase II studies, aimed at bringing immunotherapy forward in the setting of less advanced disease, as well as a number of interesting trials combining immunotherapy with conventional therapy for prostate cancer.

Recent findings

Although a number of immunotherapy trials have

SUBMITTER: Drake CG 

PROVIDER: S-EPMC3444809 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature